UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5705-5712

2008

Volltextzugriff (PDF)

Awareness, attitudes, and beliefs about palliative care: Results from a representative survey of the Italian-speaking Swiss population

PloS one, 2023-11, Vol.18 (11), p.e0294807-e0294807

2023

Volltextzugriff (PDF)

Palliative care utilization in oncology and hemato-oncology: a systematic review of cognitive barriers and facilitators from the perspective of healthcare professionals, adult patients, and their families

BMC palliative care, 2020-04, Vol.19 (1), p.47-17, Article 47

2020

Volltextzugriff (PDF)

KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors

Clinical cancer research, 2012-03, Vol.18 (6), p.1769-1776

2012

Volltextzugriff (PDF)

A qualitative exploration of interactional and organizational determinants of collaboration in cancer palliative care settings: Family members’, health care professionals’ and key informants’ perspectives

PloS one, 2021-10, Vol.16 (10), p.e0256965-e0256965

2021

Volltextzugriff (PDF)

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

PloS one, 2009-10, Vol.4 (10), p.e7287-e7287

2009

Volltextzugriff (PDF)

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2212-2217

2007

Volltextzugriff (PDF)

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

Journal of clinical medicine, 2022-12, Vol.11 (24), p.7523

2022

Volltextzugriff (PDF)

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

Clinical cancer research, 2011-07, Vol.17 (14), p.4901-4914

2011

Volltextzugriff (PDF)

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

The lancet oncology, 2008-02, Vol.9 (2), p.132-138

2008

Volltextzugriff (PDF)

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3217-3223

2007

Volltextzugriff (PDF)

Defining new criteria for selection of cell-based intestinal models using publicly available databases

BMC genomics, 2012-06, Vol.13 (1), p.274-274, Article 274

2012

Volltextzugriff (PDF)

Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3702-3708

2008

Volltextzugriff (PDF)

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3695-3701

2008

Volltextzugriff (PDF)

Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer

Journal of clinical oncology, 2002-04, Vol.20 (7), p.1759-1766

2002

Volltextzugriff (PDF)

O.5.3 - Communication in palliative care: Results: from a mixed-methods study in Italian-speaking Switzerland: Presenter(s): Nicaola Diviani, Swiss Paraplegic Research / University of Lucerne, Switzerland

Patient education and counseling, 2023-04, Vol.109

2023

Volltextzugriff (PDF)

Communication in palliative care: Results: from a mixed-methods study in Italian-speaking Switzerland

Patient education and counseling, 2023-04, Vol.109, p.12

2023

Volltextzugriff (PDF)

A qualitative analysis of educational, professional and socio-cultural issues affecting interprofessional collaboration in oncology palliative care

Patient education and counseling, 2022-09, Vol.105 (9), p.2976-2983

2022

Volltextzugriff (PDF)

Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects

Journal of gastrointestinal oncology, 2018-04, Vol.9 (2), p.377-389

2018

Volltextzugriff (PDF)

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Cancer research (Chicago, Ill.), 2009-03, Vol.69 (5), p.1851-1857

2009

Volltextzugriff (PDF)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab

Oncotarget, 2021-05, Vol.12 (11), p.1046-1056

2021

Volltextzugriff (PDF)

Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis

Endocrine, 2019-06, Vol.64 (3), p.456-468

2019

Volltextzugriff (PDF)

Choosing wisely in oncology: necessity and obstacles

ESMO open, 2018, Vol.3 (5), p.e000382-e000382, Article e000382

2018

Volltextzugriff (PDF)

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

European journal of cancer (1990), 2018-01, Vol.89, p.82-89

2018

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(55)
Berichte
(3)

Sprache

Englisch
(58)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(36)
Oncology
(31)
Humans
(29)
Male
(25)
Middle Aged
(23)
Aged
(21)
Female
(20)
Adult
(16)
Tumors
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Treatment Outcome
(12)
Gastroenterology. Liver. Pancreas. Abdomen
(11)
Aged, 80 And Over
(10)
Antineoplastic Agents - Therapeutic Use
(9)
Chemotherapy
(9)
Adenocarcinoma - Drug Therapy
(8)
Mutation
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Awareness, attitudes, and beliefs about palliative care: Results from a representative survey of the Italian-speaking Swiss population

Palliative care utilization in oncology and hemato-oncology: a systematic review of cognitive barriers and facilitators from the perspective of healthcare professionals, adult patients, and their families

KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors

A qualitative exploration of interactional and organizational determinants of collaboration in cancer palliative care settings: Family members’, health care professionals’ and key informants’ perspectives

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

A Pilot, Prospective, Observational Study to Investigate the Value of NGS in Liquid Biopsies to Predict Tumor Response After Neoadjuvant Chemo-Radiotherapy in Patients With Locally Advanced Rectal Cancer: The LiBReCa Study

Defining new criteria for selection of cell-based intestinal models using publicly available databases

Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer

O.5.3 - Communication in palliative care: Results: from a mixed-methods study in Italian-speaking Switzerland: Presenter(s): Nicaola Diviani, Swiss Paraplegic Research / University of Lucerne, Switzerland

Communication in palliative care: Results: from a mixed-methods study in Italian-speaking Switzerland

A qualitative analysis of educational, professional and socio-cultural issues affecting interprofessional collaboration in oncology palliative care

Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab

Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis

Choosing wisely in oncology: necessity and obstacles

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

Suchergebnisse filtern